Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022

Surie, Diya; Bonnell, Levi; Adams, Katherine; Gaglani, Manjusha; Ginde, Adit A.; Douin, David J.; Talbot, H. Keipp; Casey, Jonathan D.; Mohr, Nicholas M.; Zepeski, Anne; McNeal, Tresa; Ghamande, Shekhar; Gibbs, Kevin W.; Files, D. Clark; Hager, David N.; Shehu, Arber; Frosch, Anne P.; Erickson, Heidi L.; Gong, Michelle N.; Mohamed, Amira; Johnson, Nicholas J.; Srinivasan, Vasisht; Steingrub, Jay S.; Peltan, Ithan D.; Brown, Samuel M.; Martin, Emily T.; Khan, Akram; Bender, William S.; Duggal, Abhijit; Wilson, Jennifer G.; Qadir, Nida; Chang, Steven Y.; Mallow, Christopher; Rivas, Carolina; Kwon, Jennie H.; Exline, Matthew C.; Lauring, Adam S.; Shapiro, Nathan I.; Halasa, Natasha; Chappell, James D.; Grijalva, Carlos G.; Rice, Todd W.; Stubblefield, William B.; Baughman, Adrienne; Womack, Kelsey N.; Hart, Kimberly W.; Swan, Sydney A.; Zhu, Yuwei; DeCuir, Jennifer; Tenforde, Mark W.; Patel, Manish M.; McMorrow, Meredith L.; Self, Wesley H.; Calhoun, Nicole; Herrick, Judy; Hoffman, Eric; McKillop, Amanda; Murthy, Kempapura; Smith, Michael; Zayed, Martha; De Souza, Lesley; Kozikowski, Lori-Ann; Ouellette, Scott; Ashok, Kiran; Gole, Susan; King, Alexander; Mehkri, Omar; Poynter, Bryan; ten Lohuis, Caitlin; Stanley, Nicholas; Caspers, Sean; Hendrickson, Audrey; Kaus, Olivia; Taghizadeh, Leyla; Tordsen, Walker; Aston, Valerie; Bowers, Robert; Jorgensen, Jeffrey; King, Jennifer; Ali, Harith; Rothman, Richard E.; Chen, Jen-Ting; Nair, Rahul; Allada, Gopal; Briceno, Genesis; Giovanni, Shewit; Hubel, Kinsley A.; Martinez, Jesus; Oh, Minn; Pak, Jonathan; Pena, Jose; Gordon, Alexandra Jun; Levitt, Joe; Perez, Cynthia; Roque, Jonasel; Visweswaran, Anita; Karow, Sarah; Khan, Maryiam; Klingler, Austin; Pannu, Sarah; Smith, David; Schwartz, Elizabeth; Snyder, Connor; So, Madison; So, Preston; Swoope, Gabrielle; Weigand, Michael; Carricato, Michael; Chambers, Ian; Driver, Conner; Goff, Jennifer; Huynh, David; Jensen, Kelly; Chandrasekaran, Sukantha; Frankel, Trevor; Garner, Omai; Fairfield, Catherine; Landers, Shannon; Nassar, Paul; Williams, Cameron; Gershengorn, Hayley; Bielak, Ramsay; Blair, Christopher; Fitzsimmons, William J.; Fong, Rebecca; Gilbert, Julie; McSpadden, EJ; Thomas, Lara; Truscon, Rachel; Valvano, Weronika Damek; Anderson, Layla A.; Crider, Christine D.; Paulson, Thomas C.; Steinbock, Kyle A.; Blair, Marica; Ezzell, Lauren J.; Hargrave, Samarian J.; Kampe, Christy; Johnson, Jakea; Luther, Jennifer L.; McHenry, Rendie E.; Peterson, Bryan P. M.; Pulido, Claudia Guevara; Short, Laura L.; Whitsett, Margaret E.; Hicks, Madeline; Landreth, Leigha; LaRose, Mary; Parks, Lisa; Babcock, Hilary; Hink, Tiffany; Jolani, Kevin; McDonald, David; O’Neal, Caroline; Parikh, Bijal; Parrish, Katie; Samuels, Carleigh

doi:10.15585/mmwr.mm7142a3|10.1056/NEJMc2210093|10.1101/2022.08.31.22279444v1.full.pdf|10.1101/2022.07.25.22277996v1.full.pdf|10.1056/NEJMoa2208343|10.15585/mmwr.mm7107e2|10.1056/NEJMc2206725

Back to Previous Page

Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022

10 21 2022

By Surie, Diya ; Bonnell, Levi ; Adams, Katherine ; ...

Source: MMWR Morb Mortal Wkly Rep. 71(42):1327-1334

[PDF-393.97 KB]

English

Details Supporting Files You May Also Like

Details:

Alternative Title:

MMWR Morb Mortal Wkly Rep

Publisher's site:

Personal Author:

Surie, Diya ; Bonnell, Levi ; Adams, Katherine ; Gaglani, Manjusha ; Ginde, Adit A. ; ... More +

Corporate Authors:

IVY Network ; IVY Network

Description:

The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late December 2021 (1). BA.1 has since been replaced by emerging lineages BA.2 (including BA.2.12.1) in March 2022, followed by BA.4 and BA.5, which have accounted for a majority of SARS-CoV-2 infections since late June 2022 (1). Data on the effectiveness of monovalent mRNA COVID-19 vaccines against BA.4/BA.5-associated hospitalizations are limited, and their interpretation is complicated by waning of vaccine-induced immunity (2-5). Further, infections with earlier Omicron lineages, including BA.1 and BA.2, reduce vaccine effectiveness (VE) estimates because certain persons in the referent unvaccinated group have protection from infection-induced immunity. The IVY Network| assessed effectiveness of 2, 3, and 4 doses of monovalent mRNA vaccines compared with no vaccination against COVID-19-associated hospitalization among immunocompetent adults aged ≥18 years during December 26, 2021-August 31, 2022. During the BA.1/BA.2 period, VE 14-150 days after a second dose was 63% and decreased to 34% after 150 days. Similarly, VE 7-120 days after a third dose was 79% and decreased to 41% after 120 days. VE 7-120 days after a fourth dose was 61%. During the BA.4/BA.5 period, similar trends were observed, although CIs for VE estimates between categories of time since the last dose overlapped. VE 14-150 days and >150 days after a second dose was 83% and 37%, respectively. VE 7-120 days and >120 days after a third dose was 60%and 29%, respectively. VE 7-120 days after the fourth dose was 61%. Protection against COVID-19-associated hospitalization waned even after a third dose. The newly authorized bivalent COVID-19 vaccines include mRNA from the ancestral SARS-CoV-2 strain and from shared mRNA components between BA.4 and BA.5 lineages and are expected to be more immunogenic against BA.4/BA.5 than monovalent mRNA COVID-19 vaccines (6-8). All eligible adults aged ≥18 years| should receive a booster dose, which currently consists of a bivalent mRNA vaccine, to maximize protection against BA.4/BA.5 and prevent COVID-19-associated hospitalization.

Subject:

[+]

Source:

MMWR Morb Mortal Wkly Rep. 71(42):1327-1334

Pubmed ID:

36264830

Pubmed Central ID:

PMC9590291

Document Type:

Journal Article

Funding:

K23 GM129661/GM/NIGMS NIH HHSUnited States/ ; T32 GM135169/GM/NIGMS NIH HHSUnited States/

Collection(s):

Morbidity and Mortality Weekly Report (MMWR)

Main Document Checksum:

[+]

Download URL:

https://stacks.cdc.gov/view/cdc/122704/cdc_122704_DS1.pdf

File Type:

	mm7142a3-F.gif	gif
	mm7142a3-F.jpg	jpeg
	mm7142a3.nxml	xml

More +

Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022

Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022

Details:

You May Also Like

Have Questions?

CDC INFORMATION

CONNECT WITH CDC